Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed chronic-graft-versus host disease (GVHD)~* Systemic immunosuppressive treatment indicated AND no contraindication to treatment with mycophenolate mofetil~* Has undergone prior transplantation with any type of donor, hematopoietic stem cell graft, or conditioning regimen~* No clinical, laboratory, or image-based evidence known to be present at the time of enrollment and indicating a high probability of subsequent recurrent or progressive disease~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~Hepatic~* Not specified~Renal~* Not specified~Pulmonary~* No known bronchiolitis obliterans as a manifestation of chronic GVHD~Immunologic~* No fungal infection without radiographic evidence of improvement during continued antifungal therapy~* No cytomegalovirus (CMV) pneumonia without major radiographic evidence of improvement~* No other CMV infection without reduction of antigenemia or viral load during continued antiviral therapy~* No active disseminated varicella zoster viral infection~* No known hypersensitivity or allergy to MMF~Gastrointestinal~* Able to tolerate oral medication~* No lactose-intolerant children who are too young to swallow capsules~* No frank blood from the rectum~* No melena~* No known gastrointestinal ulceration~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~  * Female patients must use 2 forms of contraception 4 weeks prior to, during, and for 6 weeks after completion of study treatment~* Not hospitalized at time of enrollment~* No rare, hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT)~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* Not specified~Endocrine therapy~* Prior treatment with prednisone or equivalent allowed provided the dose was ≤ 1.0 mg/kg/day at the time of enrollment~* Concurrent systemic glucocorticoids allowed~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* Prior mycophenolate mofetil (MMF) for prevention or treatment of acute GVHD allowed provided MMF was discontinued at least 2 weeks before the diagnosis of chronic GVHD was made~* No prior systemic treatment for chronic GVHD~* No prior treatment for chronic GVHD~* Concurrent antacids allowed provided there is at least a 2-hour interval before and after administration of MMF~* No other concurrent systemic immunosuppressive treatment except cyclosporine, tacrolimus or sirolimus

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mycophenolate mofetil (Type: ACTIVE_COMPARATOR): Patients receive oral mycophenolate mofetil twice daily.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).